1. Market Research
  2. > Biotechnology Market Trends
  3. > Biotechnology Analysis & Statistics in Japan, June 2019

Biotechnology Analysis & Statistics in Japan, June 2019

Customer Support

Talk to Ahmad

+1 718 618 4302

Publishers

  • All
    • Datamonitor Healthcare

All regions

data types

1-30 of 37 reports

Drug Analysis: Fasenra

Drug Analysis: Fasenra

  • $ 10000
  • Industry report
  • February 2018

Drug OverviewFasenra (benralizumab; AstraZeneca/Kyowa Hakko Kirin) is a humanized monoclonal antibody which binds to the alpha chain of the interleukin (IL)-5 receptor on eosinophils and therefore depletes ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical, Oncology
  • Countries : United States, Japan, European Union
Drug Overview: Xolair

Drug Overview: Xolair

  • $ 10000
  • Industry report
  • February 2018

Drug OverviewXolair (omalizumab; Roche/Novartis) is a recombinant humanized monoclonal antibody for the treatment of moderate to severe persistent allergic asthma. The drug inhibits the binding of immunoglobulin ...

  • Industries : Medical Biotechnology, Therapy, Pharmaceutical, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug Analysis: Dupixent

Drug Analysis: Dupixent

  • $ 10000
  • Industry report
  • February 2018

Drug OverviewDupixent (dupilumab; Regeneron/Sanofi) is an injectable monoclonal antibody directed against the interleukin (IL)-4 receptor alpha subunit, which blocks signaling from both IL-4 and IL-13. ...

  • Industries : Medical Biotechnology
  • Countries : United States, Japan, European Union
Drug Overview: Dupixent

Drug Overview: Dupixent

  • $ 10000
  • Industry report
  • February 2018

Drug OverviewDupixent (dupilumab; Regeneron/Sanofi) is an injectable monoclonal antibody directed against the interleukin (IL)-4 receptor alpha subunit, which blocks signaling from both IL-4 and IL-13. ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug Overview: Fasenra

Drug Overview: Fasenra

  • $ 10000
  • Industry report
  • February 2018

Drug OverviewFasenra (benralizumab; AstraZeneca/Kyowa Hakko Kirin) is a humanized monoclonal antibody which binds to the alpha chain of the interleukin (IL)-5 receptor on eosinophils and therefore depletes ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical, Oncology
  • Countries : United States, Japan, European Union
Drug Analysis: Xolair

Drug Analysis: Xolair

  • $ 10000
  • Industry report
  • February 2018

Drug OverviewXolair (omalizumab; Roche/Novartis) is a recombinant humanized monoclonal antibody for the treatment of moderate to severe persistent allergic asthma. The drug inhibits the binding of immunoglobulin ...

  • Industries : Medical Biotechnology, Therapy, Pharmaceutical, Biopharmaceutical, Biopharmaceutical, Chronic Disease
  • Countries : United States, Japan, European Union
Drug Analysis: DCVAC/PCa

Drug Analysis: DCVAC/PCa

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewDCVAC/PCa (SOTIO) is a cell-based cancer vaccine composed of autologous dendritic cells which are activated to recognize a prostate cancer cell line. When infused into patients, the primed ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug Overview: DCVAC/PCa

Drug Overview: DCVAC/PCa

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewDCVAC/PCa (SOTIO) is a cell-based cancer vaccine composed of autologous dendritic cells which are activated to recognize a prostate cancer cell line. When infused into patients, the primed ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug Analysis: Mircera

Drug Analysis: Mircera

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewMircera (methoxy polyethylene glycol-epoetin beta; Roche/Vifor/Chugai) is a novel erythropoiesis-stimulating agent (ESA) designated as a continuous erythropoietin receptor activator. The drug ...

  • Industries : Medical Biotechnology
  • Countries : United States, Japan, European Union, Europe
Drug Overview: Epogen

Drug Overview: Epogen

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewEpogen (epoetin alfa; Amgen/Kyowa Hakko Kirin/Johnson&Johnson) is an erythropoiesis-stimulating agent administered by intravenous or subcutaneous injection, and is indicated for the treatment ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug Analysis: Epogen

Drug Analysis: Epogen

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewEpogen (epoetin alfa; Amgen/Kyowa Hakko Kirin/Johnson and Johnson) is an erythropoiesis-stimulating agent administered by intravenous or subcutaneous injection, and is indicated for the treatment ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug Analysis: NeoRecormon

Drug Analysis: NeoRecormon

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewNeoRecormon (epoetin beta; Roche/Chugai) is an erythropoiesis-stimulating agent (ESA) administered by intravenous (IV) or subcutaneous (SC) injection, and is indicated for the treatment of ...

  • Industries : Medical Biotechnology
  • Countries : Japan, European Union
Drug Overview: NeoRecormon

Drug Overview: NeoRecormon

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewNeoRecormon (epoetin beta; Roche/Chugai) is an erythropoiesis-stimulating agent (ESA) administered by intravenous (IV) or subcutaneous (SC) injection, and is indicated for the treatment of ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : Japan, European Union
Drug Overview: Aranesp

Drug Overview: Aranesp

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewAranesp (darbepoetin alfa; Amgen/Kyowa Hakko Kirin) is a recombinant human erythropoietin product administered by intravenous or subcutaneous injection, and is indicated for the treatment ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug Overview: Mircera

Drug Overview: Mircera

  • $ 10000
  • Industry report
  • January 2018

Drug Overview Mircera (methoxy polyethylene glycol-epoetin beta; Roche/Vifor/Chugai) is a novel erythropoiesis-stimulating agent (ESA) designated as a continuous erythropoietin receptor activator. The ...

  • Industries : Medical Biotechnology
  • Countries : United States, Japan, European Union, Europe
Drug Analysis: Aranesp

Drug Analysis: Aranesp

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewAranesp (darbepoetin alfa; Amgen/Kyowa Hakko Kirin) is a recombinant human erythropoietin product administered by intravenous or subcutaneous injection, and is indicated for the treatment ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Crohn’s Disease: Treatment

Crohn’s Disease: Treatment

  • $ 3739
  • Industry report
  • December 2017

DescriptionDatamonitor Healthcare surveyed 240 gastroenterologists in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) to gain insight into Crohn’s disease diagnosis, ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical, Pharmaceutical
  • Countries : United States, Japan, European Union
Drug analysis: Erbitux

Drug analysis: Erbitux

  • $ 10000
  • Industry report
  • December 2017

Drug OverviewErbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA) is a chimeric monoclonal antibody (MAb) that binds to the extracellular domain of epidermal growth factor receptor (EGFR). The ...

  • Industries : Therapy, Medical Biotechnology
  • Countries : United States, Japan, European Union
Drug analysis: C-Cure

Drug analysis: C-Cure

  • $ 10000
  • Industry report
  • December 2017

Drug OverviewC-Cure is a bone marrow-derived stem cell therapy aimed at regenerating cardiac tissue following severe damage due to myocardial infarctions. C-Cure consists of a patient’s own cells harvested ...

  • Industries : Medical Biotechnology, Chronic Disease, Biopharmaceutical, Biopharmaceutical, Pathology
  • Countries : United States, Japan, European Union
Drug analysis: Vectibix

Drug analysis: Vectibix

  • $ 10000
  • Industry report
  • December 2017

Drug OverviewVectibix (panitumumab; Amgen/Takeda) is a fully human immunoglobulin G2 monoclonal antibody that binds to the extracellular domain of the epidermal growth factor receptor (EGFR). This prevents ...

  • Industries : Medical Biotechnology, Cancer, Therapy, Pathology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug Analysis: Multikine

Drug Analysis: Multikine

  • $ 10000
  • Industry report
  • December 2017

Drug OverviewMultikine is an investigational immunomodulator composed of a proprietary cocktail of naturally occurring cytokines such as interleukins, interferons, chemokines, and colony-stimulating factors. ...

  • Industries : Medical Biotechnology
  • Countries : United States, Japan, European Union
Drug Analysis: Mavenclad

Drug Analysis: Mavenclad

  • $ 10000
  • Industry report
  • November 2017

Drug OverviewMavenclad contains cladribine, a small molecule that suppresses the immune system by selectively targeting lymphocytes, which are cells that seem to be major players in MS pathological mechanisms. ...

  • Industries : Medical Biotechnology
  • Countries : United States, European Union, Japan, Europe
Gastric cancer

Gastric cancer

  • $ 5000
  • Industry report
  • July 2016

Pipeline therapies will look to fulfil many areas of high unmet need left by the lack of targeted therapies approved for the treatment of gastric cancer.This report addresses the following questions:- ...

  • Industries : Cancer, Pathology
  • Countries : Japan, United States, East Asia, European Union, North America, Europe
Breast cancer: triple - negative

Breast cancer: triple - negative

  • $ 5000
  • Industry report
  • May 2016

The aggressive nature of triple-negative breast cancer and a lack of targeted therapies creates opportunities for pipeline candidates to fulfil areas of high unmet need.This report addresses the following ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan, North America, Europe, East Asia
NHL: Diffuse large Bcell lymphoma

NHL: Diffuse large Bcell lymphoma

  • $ 5000
  • Industry report
  • May 2016

An increase in disease prevalence and the launch of new targeted therapies across a range of treatment settings will drive the growth of the diffuse large B-cell lymphoma (DLBCL) market during 2016–25 ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union, North America, East Asia, Europe
Acute lymphoblastic leukemia

Acute lymphoblastic leukemia

  • $ 5000
  • Industry report
  • April 2016

The entry of CAR-T therapies will offset the generic erosion of the TKI class to drive huge growth in the acute lymphoblastic leukemia (ALL) market.This report addresses the following questions:- In which ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union, North America, East Asia, Europe
NHL: Follicular lymphoma

NHL: Follicular lymphoma

  • $ 5000
  • Industry report
  • April 2016

The follicular lymphoma (FL) market will continue to grow during 2016–25, despite the entry of biosimilars and generics, due to an increase in disease incidence and the launch of new pipeline therapies.This ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union, North America, East Asia, Europe
Anemia in chronic kidney disease

Anemia in chronic kidney disease

  • $ 5000
  • Industry report
  • April 2016

The launch of novel HIF inhibitor roxadustat will offset biosimilar erosion of Epogen to drive market growth.This report addresses the following questions: - What does the future look like for the ery ...

  • Industries : Pathology, Healthcare, Chronic Disease
  • Countries : United States, Japan, European Union, East Asia, North America, Europe
NHL: Mantle cell lymphoma

NHL: Mantle cell lymphoma

  • $ 5000
  • Industry report
  • April 2016

An increase in incident cases, combined with the expanded use of costly treatments such as Imbruvica and Revlimid, will drive the growth of the mantle cell lymphoma (MCL) market during 2016–25.This report ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan, North America, Europe, East Asia
Breast cancer: HR+/HER2-

Breast cancer: HR+/HER2-

  • $ 5000
  • Industry report
  • April 2016

Ibrance’s continued uptake and the approvals of several pipeline therapies will drive the growth of the HR+/HER2- breast cancer market.This report addresses the following questions:- Which branded therapies ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan, North America, Europe, East Asia

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on